VMVAX stock sentiment todayVanguard Morningstar Mid-Cap Value Index Fund Admiral Shares

A premier low-cost play on the mid-cap value rotation as investors flee overstretched mega-cap tech valuations.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for VMVAX. Not financial advice.

While specific headlines are quiet, the broader market narrative is shifting toward 'broadening out.' Analysts are increasingly favoring mid-cap value as a hedge against a potential 'hard landing' or a cooling AI trade, viewing this segment as the 'sweet spot' for valuation recovery.

• ·Rotation from Growth to Value
• ·Anticipation of Fed rate cuts benefiting mid-sized balance sheets
• ·Low expense ratio (0.07%) driving passive inflows

VMVAX tracks the Morningstar US Mid Broad Value Index, offering a high-quality tilt with a P/E ratio significantly lower than the S&P 500 (approx. 15-16x vs 22x). The fund maintains strong diversification across financials, industrials, and consumer staples.

• ·Expense Ratio: 0.07% (87% lower than peer average)
• ·Price-to-Earnings: ~15.8x
• ·Return on Equity: ~14.2%
• ·Dividend Yield: ~2.15%

• ·Exposure to regional banks which face ongoing margin pressure
• ·Economic cyclicality sensitivity in the industrial holdings
• ·Lower liquidity compared to large-cap counterparts

How direct competitors stack up against VMVAX right now.

• NEUTRAL
  VOEVanguard Mid-Cap Value ETF

  COLDER — while similar, VOE tracks the CRSP index which currently holds a slightly higher P/E and less concentrated quality tilt than the Morningstar index.

  See full analysis →
• COLD
  IWSiShares Russell Mid-Cap Value ETF

  COLDER — significantly higher expense ratio (0.23%) and higher volatility due to a broader, less screened constituent list.

  See full analysis →
• NEUTRAL
  JJVIXJPMorgan Mid Cap Value Fund

  COLDER — actively managed with much higher fees (0.80%+) that historically struggle to outperform VMVAX net-of-fees.

  See full analysis →